Arcadia Biosciences Inc.’s (RKDA) shares were up 28% in premarket hours on Monday after the company received an industrial hemp pilot program license from Hawaii’s Department of Agriculture.
The license allows the company to cultivate industrial hemp in Hawaii for research purposes through its new unit, Arcadia Specialty Genomics. Arcadia will start planting on ten acres of leased land next month. Hawaii is the first state to commence this program, which will also allow the commercial sale of hemp products.
Last week, Arcadia unveiled its new division, Arcadia Specialty Genomics, which will focus on improving the quality, yield and climate resiliency of cannabis. The company’s stock jumped 68% on the announcement.
Read: Arcadia Biosciences enters cannabis market, shares soar 68%
Matt Plavan, CFO of Arcadia Biosciences and President of Arcadia Specialty Genomics said, “Industrial hemp, along with all strains of cannabis, are decades behind other agricultural crops in terms of improved plant genetics. With the explosive market growth projected in the industrial hemp and derivative markets, growers will need the very best hemp strains to meet demand, minimize waste, and ensure consistent quality. As the only company working in the cannabis industry with proven track record of improving plants and commercializing food ingredients from agricultural products using non-GM techniques, we’re ideally positioned to help hemp growers and end-users benefit from better hemp strains.”
The marijuana sector has been seeing rapid growth over the past couple of years. According to market research firm, Brightfield Group, cannabis sales are projected to reach $22 billion by 2022.
We’re on Flipboard! Follow us to receive the latest stock market, earnings and financial news at your fingertips.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on